Overview

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

Status:
Completed

Trial end date:
2017-07-06

Target enrollment:

Participant gender:

Summary

To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Donepezil
Memantine